Circulating progenitor cells in patients with familial hypercholesterolemia

Area of Science:

• Cardiovascular Medicine
• Genetics
• Hematology

Background:

• Familial hypercholesterolemia (FH) is a genetic disorder characterized by extremely high low-density lipoprotein cholesterol (LDL-C) levels, accelerating atherosclerosis.
• Lipoprotein apheresis is a key treatment for FH, reducing cardiovascular events.
• Circulating progenitor cells (CPCs) reflect vascular health and reparative capacity; lower levels correlate with poorer outcomes.

Purpose of the Study:

• To evaluate the short-term impact of lipoprotein apheresis on CPC levels in FH patients undergoing stable therapy.
• To test the hypothesis that apheresis enhances vascular repair by mobilizing CPCs, in addition to lipid reduction.

Main Methods:

• Eight FH patients (1 homozygous, 7 heterozygous) on stable apheresis therapy for ≥3 months had CPCs measured pre- and post-apheresis.
• Results were compared to age-matched hyperlipidemic (HLP) patients on statins and healthy controls.

Main Results:

• FH patients exhibited significantly higher baseline levels of CD34+/CD133+ and CD34+/CD133+/CXCR4+ CPCs than HLP and healthy subjects.
• No significant change in CPC counts was observed two hours after a single lipoprotein apheresis session.

Conclusions:

• Elevated baseline CPC counts in FH patients suggest an inherent activation of vascular repair mechanisms in this high-risk group.
• Further research is required to understand the dynamics of CPC levels in FH versus HLP populations over time.